

# Key Information Document ("KID")

Leverage Shares plc

LS ARK Genomic Revolution Tracker ETP

## Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

## Product


<b>Product:</b>	LS ARK Genomic Revolution Tracker ETP ("ETP Securities")
<b>PRIP Manufacturer:</b>	Leverage Shares Plc (the "Issuer")
<b>Product ISIN:</b>	XS2399368062
<b>Website:</b>	<a href="https://leverageshares.com/">https://leverageshares.com/</a>
<b>Telephone:</b>	+1 203 883-9646
<b>Regulated by:</b>	Central Bank of Ireland and Financial Conduct Authority are responsible for supervising Leverage Shares Plc in relation to this Key Information Document.
<b>Document valid as at:</b>	04 March 2025

**You are about to purchase a product that is not simple and may be difficult to understand.**

## What is this product?

<b>Type:</b>	<p>Collateralised Exchange Traded Securities.</p> <p>The return of the product depends on the performance of an underlying asset. Please consider that there is no capital protection against market risk.</p>
<b>Term:</b>	<p>This product does not have a fixed term. The term will depend on how long you choose to hold the product, however the ETP Securities have a scheduled maturity date of 09 November 2071.</p> <p>The ETP securities may be redeemed prior to the scheduled maturity date, if: (1) the Issuer redeems all of the ETP Securities in the series following five calendar days written notice to you; (2) an event of default occurs; or (3) a mandatory redemption event occurs. A detailed description of early redemption events can be found in the prospectus in the Terms and Conditions of the ETP Securities.</p>
<b>Objectives:</b>	<p>The objective of the LS ARK Genomic Revolution Tracker ETP is to track the ARK Genomic Revolution Tracker Investment Strategy, (the 'Investment Strategy') which is designed to provide 1:1 exposure to the performance of ARK Genomic Revolution ETF (the "Reference Asset"), minus a fee. It invests all subscription proceeds and dividends received (net of taxes) directly into Reference Assets.</p> <p>The price of the ETP Securities is linked to the performance of the Reference Asset, which means that the price will rise when the price of the Reference Asset rises and fall when the price of the Reference Asset falls.</p> <p>The underlying assets in respect of this product are held in the margin account (the "Margin Account") and are as follows: the Reference Assets, any cash balances and any ancillary assets (which are assets not required for investment to track the Investment Strategy and are held as cash amounts standing to the credit of the Margin Account or invested in sovereign debt in the currency of denomination of the ETP Securities with an original maturity of less than one month and minimum credit ratings) (the "Collateral Assets").</p> <p>The Issuer's payment obligations in respect of the ETP Securities will be funded by liquidating the Collateral Assets.</p> <p>The ETP Securities are non-interest bearing and are not principal protected and you may lose some or all of your investment.</p> <p>You have no right to dividends from the Reference Assets, nor are you entitled to any additional rights arising from the Reference Assets (such as voting rights).</p>
<b>Intended retail investor:</b>	<p>The ETP securities are intended for retail investors who: (i) have specific knowledge or experience of investing in similar products and in financial markets, and have the ability to understand the product and its risks and rewards; (ii) are seeking an investment that reflects an expectation that the Reference Asset will increase in value over time, (iii) may bear a total loss of the amount invested; and (iv) have a long investment horizon in line with the recommended holding period stated below.</p>

## What are the risks and what could I get in return?



Lower risk

Higher risk



The risk indicator assumes you keep the product for 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your product easily, or you may have to sell at a price that significantly impacts on how much you get back.

### Risk indicator

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets.

We have classified this product as class 6 out of 7, which is the second-highest risk class.

This rates the potential losses from future performance at a high level, and poor market conditions are very likely to impact the capacity to pay you.

**Be aware of currency risk. If you buy this product in a currency different than USD, the final return you will get will depend on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.**

This product does not include any protection from future market performance so you could lose some or all of your investment.

## Performance Scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of LS ARK Genomic Revolution Tracker ETP over the last 10 years. Markets could develop very differently in the future.

Recommended holding period: 5 years Example Investment: USD 10 000 Scenarios		If you exit after 1 year	If you exit after 5 years
<b>Minimum</b>	There is no minimum guaranteed return. You could lose some or all of your investment.		
<b>Stress scenario</b>	<b>What might you get back after costs</b>	USD 970	USD 685.14
	Average return each year	-90.30%	-41.50%
<b>Unfavourable scenario</b>	<b>What might you get back after costs</b>	USD 3091	USD 4158.84
	Average return each year	-69.09%	-16.09%
<b>Moderate scenario</b>	<b>What might you get back after costs</b>	USD 10451	USD 14084.60
	Average return each year	4.51%	7.09%
<b>Favourable scenario</b>	<b>What might you get back after costs</b>	USD 37553	USD 75735.22
	Average return each year	275.53%	49.92%

The stress scenario shows what you might get back in extreme market circumstances.

Unfavourable: This type of scenario occurred for an investment between 20 January 2021 and 03 March 2025. Moderate: This type of scenario occurred for an investment between 26 March 2015 and 27 March 2020. Favourable: This type of scenario occurred for an investment between 11 February 2016 and 12 February 2021.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your adviser or distributor and any on exchange bid/offer spreads. The figures do not take into account your personal tax situation, which may also affect how much you get back.

## What happens if Leverage Shares plc is unable to pay out?

The product is not protected by the Irish Deposit Guarantee Scheme or any other investor compensation or guarantee scheme. If we fail to make a payment when due, the trustee (Apex Corporate Trustees (UK) Limited) can enforce the security over the Collateral Assets. Once the trustee has enforced the security it can then sell the Collateral Assets and use of the proceeds of this sale to pay the amount owed to you under the ETP Securities. The proceeds of such sale may not be enough to cover all amounts owed to you under the ETP Securities and you may lose some of all of your investment.

## What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- USD 10 000 is invested.

Investment USD 10 000	If you exit after 1 year	If you exit after 5 years
<b>Total costs</b>	USD 110.01	USD 796
Annual cost impact (*)	1.10%	1.10%

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 8.28% before costs and 7.09% after costs.

### Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
<b>Entry costs</b>	We do not charge an entry fee for this product when purchased on exchange. *	<b>USD 0</b>
<b>Exit costs</b>	We do not charge an exit fee for this product when purchased on exchange. *	<b>USD 0</b>
Ongoing costs taken each year		If you exit after 1 year
<b>Management fees and other administrative or operating costs</b>	1.10% of the value of your investment per year. This is an estimate based on actual costs over the last year.	<b>USD 110</b>
<b>Transaction costs</b>	0.00% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	<b>USD 0.01</b>
Incidental costs taken under specific conditions		If you exit after 1 year

<b>Performance fees</b>	There is no performance fee for this product.	<b>USD 0</b>
-------------------------	---	--------------

(\*) Investors dealing via stock exchanges will be subject to bid/offer spreads and pay fees charged by stock brokers. Such spreads can change at any time and can be observed in the exchanges where the ETP Securities are listed and traded. Investors can obtain from their stock brokers the fees they charge for dealing in the ETP Securities. Authorised participants dealing directly with Leverage Shares plc will pay transaction costs.

## How long should I hold it and can I take my money out early?

**Recommended minimum holding period: 5 years**

Recommended holding period: 5 years.

You may trade this product on the stock exchanges where it is listed at your own discretion. You may choose to sell your ETP Securities prior to their maturity in accordance with your investment objectives. You should be aware that the ETP Securities may not be readily sold and the value of the ETP Securities may be substantially less than the price you paid for them.

The Issuer may terminate this product unilaterally, and in certain compulsory redemption events may do so on very short notice in accordance with the prospectus.

## How can I complain?

Please feel free to contact Leverage Shares plc:

**Address:** 2nd Floor, Block 5, Irish Life Centre, Abbey Street Lower, Dublin 1, D01 P767  
**Website:** <https://leverageshares.com/>  
**E-mail:** [info@leverageshares.com](mailto:info@leverageshares.com)

## Other relevant information

For more detailed information on the Issuer, such as the prospectus as well as the latest annual and semi-annual report, can be obtained free of charge online at <https://leverageshares.com/>. These documents are available in English. For more details about the ETP securities, please refer to the prospectus, which is available at <https://leverageshares.com/>.